Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Alzheimer’s disease (AD) is the most common type of dementia affecting people over 65 years of age. The hallmarks of AD are the extracellular deposits known as amyloid β plaques and the intracellular neurofibrillary tangles, both of which are the principal players involved in synaptic loss and neuronal cell death. Tau protein and Aβ fragment 1–42 have been investigated so far in cerebrospinal fluid as a potential AD biomarkers. However, an urgent need to identify novel biomarkers which will capture disease in the early stages and with better specificity remains. High-throughput proteomic and pathway analysis of hippocampal tissue provides a valuable source of disease-related proteins and biomarker candidates, since it represents one of the earliest affected brain regions in AD. Results: In this study 2954 proteins were identified (with at least 2 peptides for 1203 proteins) from both control and AD brain tissues. Overall, 204 proteins were exclusively detected in AD and 600 proteins in control samples. Comparing AD and control exclusive proteins with cerebrospinal fluid (CSF) literature-based proteome, 40 out of 204 AD related proteins and 106 out of 600 control related proteins were also present in CSF. As most of these proteins were extracellular/secretory origin, we consider them as a potential source of candidate biomarkers that need to be further studied and verified in CSF samples. Conclusions: Our semiquantitative proteomic analysis provides one of the largest human hippocampal proteome databases. The lists of AD and control related proteins represent a panel of proteins potentially involved in AD pathogenesis and could also serve as prospective AD diagnostic biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“Together with temporal lobe, hippocampus is one of the earliest affected regions in AD pathology, when memory and cognitive functions are already impaired [17,18].”
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“The hallmarks of AD are the extracellular deposits known as amyloid β (A β ) plaques and the intracellular neurofibrillary tangles (NFT), the principal players thought to be involved in synaptic loss and neuronal cell death [1,2].”
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“The hallmarks of AD are the extracellular deposits known as amyloid β (Aβ) plaques and the intracellular neurofibrillary tangles (NFT), the principal players thought to be involved in synaptic loss and neuronal cell death [1,2].”
Blennow, K., Wallin, A., Ågren, H., Spenger, C., Siegfried, J., & Vanmechelen, E. (1995) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815140 · Cited by 789
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease
Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · cited 1×
“CSF amyloid β 1–42 fragment (Aβ 1–42) has shown about 50% decrease in AD patients in comparison to cognitively normal individuals [4,5], however it is not”
BackgroundSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections
Braak, H., & Braak, E. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00661.x · Cited by 598 · cited 1×
“Together with temporal lobe, hippocampus is one of the earliest affected regions in AD pathology, when memory and cognitive functions are already impaired [17,18].”
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Xuan, Y., Sondermann, J., Schmidt, M., Gomez-Varela, D., & Reiter, L. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000314 · Cited by 492
Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease
Drummond, E., Nayak, S., Faustin, A., Pires, G., Hickman, R. A., Askenazi, M., Cohen, M., Haldiman, T., Kim, C., Han, X., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1691-0 · Cited by 239
A role for tau at the synapse in Alzheimer’s disease pathogenesis
Pooler, A. M., Noble, W., & Hanger, D. P. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.018 · Cited by 203
“Furthermore, analysis of AD brains reveals alterations in genes involved in synaptic vesicle trafficking in the hippocampus (Begcevic et al., 2013) and in frontal cortex (Yao et al., 2003).”
BackgroundAmyloid-β Peptide Induces Mitochondrial Dysfunction by Inhibition of Preprotein Maturation
Mossmann, D., Vögtle, F.-N., Taskin, A. A., Teixeira, P. F., Ring, J., Burkhart, J. M., Burger, N., Pinho, C. M., Tadic, J., Loreth, D., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.07.024 · Cited by 201
RNA binding proteins co-localize with small tau inclusions in tauopathy
Maziuk, B. F., Apicco, D. J., Cruz, A. L., Jiang, L., Ash, P. E. A., da Rocha, E. L., Zhang, C., Yu, W. H., Leszyk, J., Abisambra, J. F., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0574-5 · Cited by 151
“Proteomic studies of complexes containing tau from the rTg4510 mouse model and human AD tissues also report RNA binding and nucleotide binding proteins in their results, as well as multiple heat shock proteins and chaperones [4, 25]; work from the Abrisambra laboratory also dir-”
Background
Metadata
- Authors
- Begcevic, I., Kosanam, H., Martínez-Morillo, E., Dimitromanolakis, A., Diamandis, P., Kuzmanov, U., Hazrati, L.-N., & Diamandis, E. P.
- Venue
- Clinical Proteomics
- Published
- 2013-05-01
- Volume
- 10
- Issue
- 1
- Pages
- 5-5
- ISSN
- 1542-6416 (ISSN-L)
- 1559-0275
- OpenAlex
- W2129357983
- Cited by
- 58
- References
- 7
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains. https://app.cochat.ai/papers/10.1186/1559-0275-10-5
- The paper
- Begcevic, I., Kosanam, H., Martínez-Morillo, E., Dimitromanolakis, A., Diamandis, P., Kuzmanov, U., Hazrati, L.-N., & Diamandis, E. P. (2013). Semiquantitative proteomic analysis of human hippocampal tissues from Alzheimer’s disease and age-matched control brains. Clinical Proteomics. https://doi.org/10.1186/1559-0275-10-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.